Home > Insider Trading > Filing (0001140361-25-020376)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	Biological Products, (No Disgnostic Substances) (2836)	562590442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1554353	P. Lawrence Guiheen	C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446		No	No	No	No

Transaction Summary

Sold:	9,000 shares	Avg. Price: $20.29	Total Value: $182,635.80
Number of Shares After Transactions:	114,830 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-05-21	7,779	$5.96	122,609	No	4	M	Direct
Common Stock	Disposition	2025-05-21	7,779	$20.32	114,830	No	4	S	Direct
Common Stock	Acquisiton	2025-05-22	1,221	$5.96	116,051	No	4	M	Direct
Common Stock	Disposition	2025-05-22	1,221	$20.12	114,830	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2025-05-21	7,779	$0.00	7,779	$5.96
Common Stock	Stock Option (right to buy)	Disposition	2025-05-22	1,221	$0.00	1,221	$5.96

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,221		2026-01-28	No	4	M	Direct
0		2026-01-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	50,990	Indirect	See footnote

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 103,941 shares of common stock owned by the Reporting Person. The number of common shares reported includes a de minimis reduction by 10 shares from the amount previously reported due to a broker adjustment.
Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1 (the "Guiheen Irrevocable Trust"), of which 49,990 shares were inadvertently reported in prior reports as directly owned.
These shares are owned by the Guiheen Irrevocable Trust.
The Reporting Person is exercising this option due, in part, to its near-term expiration date.
These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.